Electric shocks plus chemo: a new way to fight melanoma?
NCT ID NCT07404605
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter cancer cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults before and after treatment to see how immune cells and blood vessels in the tumors respond. The goal is to better understand why this treatment works and how it might be improved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bleomycin or cisplatin (chemotherapy drugs) combined with electric pulses
What this could lead to
If successful, this study could reveal how electrochemotherapy boosts the immune response against melanoma, potentially leading to better combination treatments.
What could go wrong
This is an early-stage observational study focused on biological changes, not on curing the disease. The results may not directly translate into new treatments or benefit participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Institute of Oncology Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••